Beyond triple-negative breast cancer: the need to define new subtypes

References

• Cancer Statistics Registrations: Registrations of Cancer Diagnosed in 2006, England. The Office of National Statistics, The Stationery Office, London, UK (2006).
   Google Scholar
• Rakha EA, El-Sayed ME, Green AR et al. Prognostic markers in triple-negative breast cancer. Cancer109(1), 25–32 (2007).
   PubMed Web of Science ®Google Scholar
• Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res.13(15 Pt 1), 4429–4434 (2007).
   PubMed Web of Science ®Google Scholar
• Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res.13(8), 2329–2334 (2007).
   PubMed Web of Science ®Google Scholar
• Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer109(9), 1721–1728 (2007).
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology52(1), 108–118 (2008).
   PubMed Web of Science ®Google Scholar
• Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol.26(8), 1275–1281 (2008).
   PubMed Web of Science ®Google Scholar
• Gluz O, Nitz UA, Harbeck N et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann. Oncol.19(5), 861–870 (2008).
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature406(6797), 747–752 (2000).
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA98(19), 10869–10874 (2001).
   PubMed Web of Science ®Google Scholar
• Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA100(14), 8418–8423 (2003).
   PubMed Web of Science ®Google Scholar
• Weigelt B, Mackay A, A’Hern R et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol.11(4), 339–349 (2010).
   PubMed Web of Science ®Google Scholar
• Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res.11(16), 5678–5685 (2005).
   PubMed Web of Science ®Google Scholar
• Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF. Molecular classification of breast cancer: limitations and potential. Oncologist11(8), 868–877 (2006).
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med.360(8), 790–800 (2009).
   PubMed Web of Science ®Google Scholar
• Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J. Pathol.220(2), 263–280 (2010).
   PubMed Web of Science ®Google Scholar
• Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat. Rev. Clin. Oncol.6(12), 718–730 (2009).
   PubMed Web of Science ®Google Scholar
• de Ronde JJ, Hannemann J, Halfwerk H et al. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res. Treat.119(1), 119–126 (2010).
   PubMed Web of Science ®Google Scholar
• Parker JS, Mullins M, Cheang MC et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol.27(8), 1160–1167 (2009).
   PubMed Web of Science ®Google Scholar
• Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J. Clin. Oncol.26(15), 2568–2581 (2008).
   PubMed Web of Science ®Google Scholar
• Bertucci F, Finetti P, Cervera N et al. How basal are triple-negative breast cancers? Int. J. Cancer123(1), 236–240 (2008).
   PubMed Web of Science ®Google Scholar
• Cheang MC, Voduc D, Bajdik C et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res.14(5), 1368–1376 (2008).
   PubMed Web of Science ®Google Scholar
• Kreike B, van Kouwenhove M, Horlings H et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res.9(5), R65 (2007).
   PubMed Web of Science ®Google Scholar
• Rakha EA, Elsheikh SE, Aleskandarany MA et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin. Cancer Res.15(7), 2302–2310 (2009).
   PubMed Web of Science ®Google Scholar
• Rakha EA, Tan DS, Foulkes WD et al. Are triple-negative tumours and basal-like breast cancer synonymous? Breast Cancer Res.9(6), 404 (2007).
   PubMedGoogle Scholar
• Weigelt B, Horlings HM, Kreike B et al. Refinement of breast cancer classification by molecular characterization of histological special types. J. Pathol.216(2), 141–150 (2008).
   PubMed Web of Science ®Google Scholar
• Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest.26(1), 1–10 (2008).
   PubMed Web of Science ®Google Scholar
• Farmer P, Bonnefoi H, Becette V et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene24(29), 4660–4671 (2005).
   PubMed Web of Science ®Google Scholar
• Chin SF, Teschendorff AE, Marioni JC et al. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol.8(10), R215 (2007).
   PubMedGoogle Scholar
• Hu Z, Fan C, Oh DS et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics7, 96 (2006).
   PubMed Web of Science ®Google Scholar
• Teschendorff AE, Caldas C. A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer. Breast Cancer Res.10(4), R73 (2008).
   PubMedGoogle Scholar
• Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol.8(8), R157 (2007).
   PubMedGoogle Scholar
• Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res.69(10), 4116–4124 (2009).
   PubMed Web of Science ®Google Scholar
• Creighton CJ, Li X, Landis M et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl Acad. Sci. USA106(33), 13820–13825 (2009).
   PubMed Web of Science ®Google Scholar
• Jumppanen M, Gruvberger-Saal S, Kauraniemi P et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res.9(1), R16 (2007).
   Web of Science ®Google Scholar
• Silver DP, Richardson AL, Eklund AC et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J. Clin. Oncol.28(7), 1145–1153 (2010).
   PubMed Web of Science ®Google Scholar
• Haffty BG, Yang Q, Reiss M et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J. Clin. Oncol.24(36), 5652–5657 (2006).
   PubMed Web of Science ®Google Scholar
• Tischkowitz M, Brunet JS, Begin LR et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer7, 134 (2007).
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Grainge MJ, Rakha EA, Green AR, Ellis IO. Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. Breast Cancer Res. Treat.117(1), 199–204 (2009).
   PubMedGoogle Scholar
• Desmedt C, Haibe-Kains B, Wirapati P et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin. Cancer Res.14(16), 5158–5165 (2008).
   PubMed Web of Science ®Google Scholar
• Wirapati P, Sotiriou C, Kunkel S et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res.10(4), R65 (2008).
   PubMed Web of Science ®Google Scholar
• Smid M, Wang Y, Zhang Y et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res.68(9), 3108–3114 (2008).
   PubMed Web of Science ®Google Scholar
• Lin NU, Claus E, Sohl J et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer113(10), 2638–2645 (2008).
   PubMed Web of Science ®Google Scholar
• Harris LN, Broadwater G, Lin NU et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res.8(6), R66 (2006).
   PubMed Web of Science ®Google Scholar
• Fulford LG, Reis-Filho JS, Ryder K et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res.9(1), R4 (2007).
   PubMed Web of Science ®Google Scholar
• Natrajan R, Weigelt B, Mackay A et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res. Treat.121(3), 575–589 (2010).
   PubMedGoogle Scholar
• Stephens PJ, McBride DJ, Lin ML et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature462(7276), 1005–1010 (2009).
   PubMed Web of Science ®Google Scholar
• Doane AS, Danso M, Lal P et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene25(28), 3994–4008 (2006).
   PubMed Web of Science ®Google Scholar
• Turner NC, Reis-Filho JS, Russell AM et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene26(14), 2126–2132 (2007).
   PubMed Web of Science ®Google Scholar
• Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene25(43), 5846–5853 (2006).
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature434(7035), 917–921 (2005).
   PubMed Web of Science ®Google Scholar
• Azoulay S, Lae M, Freneaux P et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod. Pathol.18(12), 1623–1631 (2005).
   PubMed Web of Science ®Google Scholar
• Lae M, Freneaux P, Sastre-Garau X et al. Secretory breast carcinomas with ETV6–NTRK3 fusion gene belong to the basal-like carcinoma spectrum. Mod. Pathol.22(2), 291–298 (2009).
   PubMed Web of Science ®Google Scholar
• Lambros MB, Tan DS, Jones RL et al. Genomic profile of a secretory breast cancer with an ETV6–NTRK3 duplication. J. Clin. Pathol.62(7), 604–612 (2009).
   PubMedGoogle Scholar
• Marchio C, Weigelt B, Reis-Filho JS. Adenoid cystic carcinomas of the breast and salivary glands (or ‘The Strange Case of Dr. Jekyll and Mr. Hyde’ of exocrine gland carcinomas). J. Clin. Pathol.63(3), 220–228 (2009).
   Google Scholar
• Jacquemier J, Padovani L, Rabayrol L et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J. Pathol.207(3), 260–268 (2005).
   PubMedGoogle Scholar
• Vincent-Salomon A, Gruel N, Lucchesi C et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res.9(2), R24 (2007).
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS, Milanezi F, Steele D et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology49(1), 10–21 (2006).
   PubMed Web of Science ®Google Scholar
• Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res. Treat.117(2), 273–280 (2009).
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Giordano S, Broglio K et al. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann. Oncol.17(4), 605–613 (2006).
   PubMed Web of Science ®Google Scholar
• Santini D, Ceccarelli C, Taffurelli M, Pileri S, Marrano D. Differentiation pathways in primary invasive breast carcinoma as suggested by intermediate filament and biopathological marker expression. J. Pathol.179(4), 386–391 (1996).
   PubMed Web of Science ®Google Scholar
• Arnes JB, Brunet JS, Stefansson I et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin. Cancer Res.11(11), 4003–4011 (2005).
   PubMed Web of Science ®Google Scholar
• Fulford LG, Easton DF, Reis-Filho JS et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology49(1), 22–34 (2006).
   PubMed Web of Science ®Google Scholar
• Livasy CA, Karaca G, Nanda R et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod. Pathol.19(2), 264–271 (2006).
   PubMed Web of Science ®Google Scholar
• Savage K, Leung S, Todd SK et al. Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. Breast Cancer Res. Treat.110(2), 245–256 (2008).
   PubMed Web of Science ®Google Scholar
• Tan DS, Marchio C, Jones RL et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res. Treat.111(1), 27–44 (2008).
   PubMed Web of Science ®Google Scholar
• Kim MJ, Ro JY, Ahn SH et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum. Pathol.37(9), 1217–1226 (2006).
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS, Steele D, Di Palma S et al. Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. Mod. Pathol.19(2), 307–319 (2006).
   PubMed Web of Science ®Google Scholar
• Moyano JV, Evans JR, Chen F et al. αB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J. Clin. Invest.116(1), 261–270 (2006).
   PubMed Web of Science ®Google Scholar
• Parry S, Savage K, Marchio C, Reis-Filho JS. Nestin is expressed in basal-like and triple negative breast cancers. J. Clin. Pathol.61(9), 1045–1050 (2008).
   PubMedGoogle Scholar
• Klingbeil P, Natrajan R, Everitt G et al. CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification. Breast Cancer Res. Treat.120(1), 95–109 (2010).
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res.10(16), 5367–5374 (2004).
   PubMed Web of Science ®Google Scholar
• Korsching E, Packeisen J, Agelopoulos K et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab. Invest.82(11), 1525–1533 (2002).
   PubMed Web of Science ®Google Scholar
• Manie E, Vincent-Salomon A, Lehmann-Che J et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res.69(2), 663–671 (2009).
   PubMed Web of Science ®Google Scholar
• Lakhani SR, Van De Vijver MJ, Jacquemier J et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J. Clin. Oncol.20(9), 2310–2318 (2002).
   PubMed Web of Science ®Google Scholar
• Nofech-Mozes S, Trudeau M, Kahn HK et al. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Res. Treat.118(1), 131–137 (2009).
   PubMedGoogle Scholar
• Lakhani SR, Reis-Filho JS, Fulford L et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin. Cancer Res.11(14), 5175–5180 (2005).
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Stefansson IM, Chappuis PO et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl Cancer Inst.95(19), 1482–1485 (2003).
   PubMed Web of Science ®Google Scholar
• van der Groep P, Bouter A, van der Zanden R et al. Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. J. Clin. Pathol.59(6), 611–617 (2006).
   PubMedGoogle Scholar
• Atchley DP, Albarracin CT, Lopez A et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J. Clin. Oncol.26(26), 4282–4288 (2008).
   PubMed Web of Science ®Google Scholar
• Liu X, Holstege H, van der Gulden H et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc. Natl Acad. Sci. USA104(29), 12111–12116 (2007).
   PubMed Web of Science ®Google Scholar
• McCarthy A, Savage K, Gabriel A et al. A mouse model of basal-like breast carcinoma with metaplastic elements. J. Pathol.211(4), 389–398 (2007).
   PubMed Web of Science ®Google Scholar
• Han W, Jung EM, Cho J et al. DNA copy number alterations and expression of relevant genes in triple-negative breast cancer. Genes Chromosomes Cancer47(6), 490–499 (2008).
   PubMedGoogle Scholar
• Turner N, Lambros MB, Horlings HM et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene29(14), 2013–2023 (2010).
   PubMed Web of Science ®Google Scholar
• Andre F, Job B, Dessen P et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin. Cancer Res.15(2), 441–451 (2009).
   PubMed Web of Science ®Google Scholar
• Natrajan R, Lambros MB, Rodriguez-Pinilla SM et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin. Cancer Res.15(8), 2711–2722 (2009).
   PubMedGoogle Scholar
• van Beers EH, van Welsem T, Wessels LF et al. Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res.65(3), 822–827 (2005).
   PubMed Web of Science ®Google Scholar
• Jonsson G, Naylor TL, Vallon-Christersson J et al. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res.65(17), 7612–7621 (2005).
   PubMed Web of Science ®Google Scholar
• Waddell N, Arnold J, Cocciardi S et al. Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Res. Treat. DOI: 10.1007/s10549-009-0653-1 (2009) (Epub ahead of print).
   Google Scholar
• Joosse SA, van Beers EH, Tielen IH et al. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Res. Treat.116(3), 479–489 (2009).
   PubMed Web of Science ®Google Scholar
• Matros E, Wang ZC, Lodeiro G et al.BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res. Treat.91(2), 179–186 (2005).
   PubMed Web of Science ®Google Scholar
• Bartz SR, Zhang Z, Burchard J et al. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol. Cell. Biol.26(24), 9377–9386 (2006).
   PubMed Web of Science ®Google Scholar
• Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol.26(22), 3785–3790 (2008).
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med.361(2), 123–134 (2009).
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Metcalfe K, Hanna W et al. Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer98, 1569–1577 (2003).
   PubMed Web of Science ®Google Scholar
• Byrski T, Huzarski T, Dent R et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res. Treat.115(2), 359–363 (2009).
   PubMed Web of Science ®Google Scholar
• Byrski T, Gronwald J, Huzarski T et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J. Clin. Oncol.28(3), 375–379 (2010).
   PubMed Web of Science ®Google Scholar
• Gronwald J, Byrski T, Huzarski T et al. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. J. Clin. Oncol.27(Suppl. 15s), (2009) (Abstract 502).
   Google Scholar
• McCabe N, Turner NC, Lord CJ et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res.66(16), 8109–8115 (2006).
   PubMed Web of Science ®Google Scholar
• Tutt A, Robson, M., Garber, J.E. et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J. Clin. Oncol.27(Suppl. 18s), (2009) (Abstract 501).
   Google Scholar
• O’Shaughnessy J, Osborne C, Pippen J et al. Efficacy of BSI-201, a poly(ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized Phase II trial. J. Clin. Oncol.27(Suppl. 18s), (2009) (Abstract 3).
   Google Scholar
• Linderholm BK, Hellborg H, Johansson U et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann. Oncol.20(10), 1639–1646 (2009).
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med.357(26), 2666–2676 (2007).
   PubMed Web of Science ®Google Scholar
• Miles DW, Chan A, Romieu G et al. Final overall survival (OS) results from the randomised, double-blind, placebo-controlled, Phase III AVADO study of bevacizumab (BV) plus docetaxel (D) compared with placebo (PL) plus D for the first-line treatment of locally recurrent (LR) or metastatic breast cancer (mBC). Cancer Res.69(24), 495S–495S (2009).
   Google Scholar
• O’Shaughnessy JA, Brufsky AM. RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer. Clin. Breast Cancer8(4), 370–373 (2008).
   PubMed Web of Science ®Google Scholar
• Brufsky A, Bondarenko IN, Smirnov V et al. RIBBON-2: A randomized, double-blind, placebo-controlled, Phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Cancer Res.69(24), 495S–496S (2009).
   Google Scholar
• Ryan PD, Tung NM, Isakoff SJ et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy. J. Clin. Oncol.27(Suppl. 15s), (2009) (Abstract 551).
   Google Scholar
• Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med.351(4), 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Carey LA, Rugo HS, Marcom PK et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J. Clin. Oncol.26(Suppl.), (2008) (Abstract 1009).
   Google Scholar
• Finn RS, Dering J, Ginther C et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/’triple-negative’ breast cancer cell lines growing in vitro. Breast Cancer Res. Treat.105(3), 319–326 (2007).
   PubMed Web of Science ®Google Scholar
• Huang F, Reeves K, Han X et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res.67(5), 2226–2238 (2007).
   PubMed Web of Science ®Google Scholar
• Somlo G, Atzori F, Strauss L et al. Dasatinib plus capecitabine (Cap) for progressive advanced breast cancer (ABC): Phase I study CA180004. J. Clin. Oncol.27(Suppl.), (2009) (Abstract 1012).
   PubMedGoogle Scholar
• Mirzoeva OK, Das D, Heiser LM et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res.69(2), 565–572 (2009).
   PubMed Web of Science ®Google Scholar
• Marty B, Maire V, Gravier E et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res.10(6), 101 (2008).
   PubMed Web of Science ®Google Scholar
• Stemke-Hale K, Gonzalez-Angulo AM, Lluch A et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res.68(15), 6084–6091 (2008).
   PubMed Web of Science ®Google Scholar
• Vasudevan KM, Barbie DA, Davies MA et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell16(1), 21–32 (2009).
   PubMed Web of Science ®Google Scholar
• Iorns E, Lord CJ, Grigoriadis A et al. Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS ONE4(4), e5120 (2009).
   PubMed Web of Science ®Google Scholar
• Ozaki K, Kishikawa F, Tanaka M et al. Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Sci.99(2), 376–384 (2008).
   PubMedGoogle Scholar
• Caldas-Lopes E, Cerchietti L, Ahn JH et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc. Natl Acad. Sci. USA106(20), 8368–8373 (2009).
   PubMed Web of Science ®Google Scholar
• Rahman M, Davis SR, Pumphrey JG et al. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res. Treat.113(2), 217–230 (2009).
   PubMed Web of Science ®Google Scholar
• Neve RM, Chin K, Fridlyand J et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell10(6), 515–527 (2006).
   PubMed Web of Science ®Google Scholar
• Greenman C, Stephens P, Smith R et al. Patterns of somatic mutation in human cancer genomes. Nature446(7132), 153–158 (2007).
   PubMed Web of Science ®Google Scholar
• Stephens P, Edkins S, Davies H et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat. Genet.37(6), 590–592 (2005).
   PubMed Web of Science ®Google Scholar
• Aparicio SA, Huntsman DG. Does massively parallel DNA resequencing signify the end of histopathology as we know it? J. Pathol.220(2), 307–315 (2009).
   Google Scholar